Baseline counts | |||||
---|---|---|---|---|---|
Subsets | MED | LQ | UQ | MIN | MAX |
CD 8 | 715 | 513.5 | 904.5 | 266 | 1373 |
IL-2 | 7.18 | 5.85 | 8.5 | 4.51 | 9.14 |
IL-10 | 136.22 | 30.04 | 214.39 | 0 | 234.86 |
Difference in counts after CLA treatment | |||||
Subsets | MED | LQ | UQ | MIN | MAX |
CD 8 | 45 | −35.5 | 275 | −334 | 832 |
IL-2 | 0.73 | −1.16 | 1.72 | −3.21 | 5.21 |
IL-10 | 4.31 | −76.74 | 62.57 | −211.63 | 181.03 |
Difference in counts after HOSF treatment | Â | ||||
Subsets | MED | LQ | UQ | MIN | MAX |
CD 8 | 16.5 | −261.5 | 155.5 | −470 | 227 |
IL-2 | −0.74 | −7.16 | 1.01 | −10.36 | 5.21 |
IL-10 | 54.27 | −77.79 | 352.93 | −125.04 | 615.78 |
Difference in counts between CLA and HOSF treatments | |||||
Subsets | MED | LQ | UQ | MIN | MAX |
CD 8 | 290.5 | −103.5 | 454 | −439 | 644 |
IL-2 | 1.85 | −2.86 | 6 | −4.22 | 15.57 |
IL-10 | −46.05 | −564.56 | 138.28 | −579.81 | 187.61 |
Difference in counts between baselines and end of the trial | |||||
Subsets | MED | LQ | UQ | MIN | MAX |
CD 8 | 270 | 209.5 | 395 | −118 | 1327 |
IL-2 | −2.45 | −5.85 | 20.07 | −7.01 | 144.39 |
IL-10 | 107.82 | 82.39 | 521.35 | 66.33 | 1011.57 |